Health&Life Co Ltd

Health&Life Co Ltd has a market capitalization of TWD 512 million and a price-to-book ratio of 1.6, indicating a moderate premium to its equity value. The company’s liquidity position is strong, with TWD 247.6 million in cash and equivalents and a current ratio of 2.39, suggesting it can cover short-term obligations comfortably. However, its free cash flow is negative at TWD -54 million, driven by capital expenditures of TWD -6.9 million and operational inefficiencies. Profitability metrics are weak, with a net loss of TWD -61.7 million and an operating loss of TWD -63.4 million, resulting in a negative return on equity of -19.24% and a return on assets of -8.53%. These figures fall significantly below the industry median for medical equipment firms, which typically report positive ROE and ROA in the 5–10% range. The company’s revenue is concentrated in undisclosed domestic and overseas markets, with no segment-specific breakdown provided in the latest financials. This lack of transparency limits the ability to assess geographic or product-specific risk exposure. Growth appears to be under pressure, with no clear revenue expansion evident in the latest period. The company’s operating cash flow of TWD 3.2 million is insufficient to offset its free cash flow deficit, and no significant revenue growth is projected in the next fiscal year. Risk factors include a negative net income and operating income, which could pressure liquidity if cash burn accelerates. However, the company has no immediate dilution or liquidity flags, and its debt-to-equity ratio of 0.61 suggests manageable leverage. Recent filings and transcripts do not indicate material operational or strategic changes, and the company’s last reported EPS was 0.59 TWD, consistent with a lack of earnings momentum.